Nurix Therapeutics, Inc. (NASDAQ:NRIX) Q1 2026 Earnings and Pipeline Update

Key Highlights:

• EPS Miss and Revenue Shortfall: Nurix reported an EPS of -$0.79, missing consensus estimates of approximately -$0.76 to -$0.78. Revenue came in at $6.3 million, well below expectations of around $14.25 million.
• Strong Cash Position Amid Losses: The company ended the quarter with $540.7 million in cash, cash equivalents, and marketable securities, providing a solid runway. It reported a net loss of $87.2 million.
• Pipeline Progress: Nurix continues to advance its clinical programs, including the ongoing pivotal Phase 2 DAYBreak CLL-201 trial of bexobrutideg (NX-5948) in relapsed/refractory chronic lymphocytic leukemia (CLL), with plans to initiate a confirmatory Phase 3 trial. The company also targets a 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications and is progressing partnered programs for IRAK4 (Phase 1) and STAT6 (IND-enabling).

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on developing targeted protein degraders for the treatment of cancer and inflammatory/autoimmune diseases. It operates in the biotechnology sector, with a particular emphasis on the Zacks Medical – Biomedical and Genetics industry group.

On April 8, 2026, Nurix reported financial results for the fiscal first quarter ended February 28, 2026. The company posted an EPS of -$0.79, missing estimates (surprise of roughly -4.22%). This compares to an EPS of -$0.67 in the year-ago quarter. Over the past year, Nurix has beaten EPS estimates in only a limited number of quarters.

Revenue totaled $6.3 million, significantly below consensus estimates (shortfall of approximately 57%). This represents a sharp decline from $18.5 million in the same quarter last year, primarily due to the completion of the initial research term for certain targets under the Sanofi collaboration. Nurix has a mixed track record of beating revenue estimates in recent quarters.

Financially, Nurix remains well-capitalized with $540.7 million in cash, cash equivalents, and marketable securities as of February 28, 2026 (down from $592.9 million at the end of the prior quarter). The company reported a net loss of $87.2 million. Operating expenses rose, driven by higher R&D investment (approximately $84.1 million) as the company accelerates clinical programs, along with increased G&A costs (approximately $14.6 million). Note that collaboration-heavy biotechs like Nurix can show negative gross margins in reporting due to the classification of certain costs against collaboration revenue.